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Minor histocompatibility (H) antigens are allogeneic target molecules having significant roles in alloimmune responses
after human leukocyte antigen–matched solid organ and stem cell transplantation (SCT). Minor H antigens are
instrumental in the processes of transplant rejection, graft-versus-host disease, and in the curative graft-versus-tumor
effect of SCT. The latter characteristic enabled the current application of selected minor H antigens in clinical
immunotherapeutic SCT protocols. No information exists on the global phenotypic distribution of the currently
identified minor H antigens. Therefore, an estimation of their overall impact in human leukocyte antigen–matched
solid organ and SCT in the major ethnic populations is still lacking. For the first time, a worldwide phenotype frequency
analysis of ten autosomal minor H antigens was executed by 31 laboratories and comprised 2,685 randomly selected
individuals from six major ethnic populations. Significant differences in minor H antigen frequencies were observed
between the ethnic populations, some of which appeared to be geographically correlated.
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Introduction
Minor histocompatibility (H) antigens are polymorphic
peptides that are presented on the cell surface by major
histocompatibility complex class I or II molecules [1]. These
peptides are derived from allelic cellular proteins encoded by
autosomal genes or by genes of the Y chromosome [2]. In
general, minor H antigen-encoding proteins are biallelic,
encoding an immunogenic and a nonimmunogenic allele.
Individuals homozygous for the nonimmunogenic minor H
allele can develop immune responses to cells expressing the
immunogenic minor H allele. Minor H antigen alloimmune
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antigen (HLA)–matched allogeneic solid organ and stem cell
transplantation (SCT) [3,4]. The role of minor H antigen
disparities is most thoroughly analyzed in the setting of HLA–
matched SCT, wherein powerful minor H antigen alloim-
mune reactivities have been documented in the graft-versus-
host direction (for review see [5]). Minor H antigen responses
are detected during the development of graft-versus-host
disease (GvHD) and during the curative graft-versus-tumor
(GvT) responses after HLA-matched SCT (for review see [6]).
This seemingly conﬂicting role of the minor H antigens in the
two GvH (i.e., GvHD and GvT reaction) responses was
dissected by the differential tissue distribution of minor H
antigens. In vitro studies showed differential modes of
expression of the various minor H antigens being either
ubiquitously expressed or with expression restricted to the
hematopoietic system [7,8]. Ubiquitously expressed minor H
antigens are present on many cells and tissues, including the
GvHD target organs: skin, liver, and gut. These minor H
antigens are therefore particularly relevant in the develop-
ment of GvHD. Hematopoietic system–restricted minor H
antigens are only expressed by hematopoietic cells and their
progenitors with no expression on nonhematopoietic cells.
Some of these minor H antigens can also be expressed by
tumor cells [9–12]. Minor H antigens with tissue expression
limited to cells of the hematopoietic system and/or tumor
cells are especially relevant for the GvT activity.
For example, cytotoxic T cells speciﬁc to the hemato-
poietic-restricted minor H antigens HA-1 and HA-2 eradicate
circulating leukemic cells and leukemic progenitors cells in
vitro [13,14] and in an in vivo translational mouse model [15]
and can be isolated in the course of remission of donor
lymphocyte infusion–treated patients after HLA-matched
SCT [16,17]. Currently, hematopoietic system- and tumor-
speciﬁc minor H antigenic peptides are being applied in
clinical phase I and II vaccination studies to boost the GvT
response (reviewed in [6]).
Although scarcely analyzed, minor H antigens are likely to
function as potential risks for graft rejection of HLA-
matched solid organ transplants [18]. The apparent need of
the organ transplant recipient for lifelong immunosuppres-
sive drugs supports this notion. Interestingly, a beneﬁcial
effect of minor H antigen mismatching on long-term HLA-
matched renal allograft survival has been recently described
[19]. Namely, HA-1 speciﬁc T regulator cells were present in a
patient who had discontinued immune suppression over 30 y
ago while sustaining normal kidney function. Herewith a
novel characteristic for human minor H antigens has been
disclosed with potential impact for decrement of immuno-
suppressive therapy in solid organ grafting.
Minor H antigen alloimmune responses also occur in the
physiological setting of pregnancy. Pregnancy leads to a
mutual ﬂow of cells between mother and child. The exposure
to either foreign maternal or paternal minor H antigens
during pregnancy drives the generation of minor H antigen
speciﬁc T cells in mutual direction [20,21]. To date, it is clear
that minor H antigenic responses cannot be ignored in the
nonphysiological situation of transplantation and in the
physiological setting of pregnancy, where female donors with
a history of pregnancy and cord blood are used as sources for
SCT. Moreover, various minor H antigen identiﬁcation
systems recently became available, facilitating their molecular
identiﬁcation (for overview see [2]). It is therefore timely to
estimate the potential impact of the minor H antigens
molecularly identiﬁed today in the different settings described
above. Furthermore, since the ﬁrst minor H antigen–based
clinical vaccination trials in SCT protocols have begun, it is of
great importance to estimate their potential applicability in
different ethnic groups. Hereto, information on the pheno-
type frequencies of minor H antigens is required. Population
frequency analyses of minor H antigens have so far been
performed for a limited number of minor H antigens and are
mainly limited to the White population [22]. Additional but
scarce information on some of the minor H antigen genotypes
is provided by the HapMap project [23]. The present multi-
center study reports on a worldwide analysis providing for the
ﬁrst time the global phenotype frequencies of the ten
autosomally encoded minor H antigens identiﬁed at the
initiation of the study. Using these data, geographic patterns
were additionally analyzed. Moreover, the theoretical clinical
usefulness in HLA-matched SCT of each individual minor H
antigen was estimated within six different ethnic populations.
Results
Study Populations
Genomic typing data of ten autosomally encoded minor H
antigens were obtained from 2,685 individuals from ﬁve
different continents comprising 16 different countries and
ﬁve different ethnic groups. The backgrounds of the ﬁve
ethnic groups were: (1) 305 Asian/Paciﬁc Islanders, 11.4%; (2)
162 Black, 6.0%; (3) 2,011 White, 74.9%; (4) 119 Mestizo
Mexican, 4.4%; and (5) 88 speciﬁed as ‘‘others,’’ 3.3%. The
Asian/Paciﬁc Islander group could be subdivided into South-
east Asian/Southern Chinese (10.8% of the Asian/Paciﬁc
Islander group), Asian Indian (67.9%), Japanese (20.3%),
and Asian not otherwise speciﬁed (1.0%). The Black
population consisted of 102 African Americans (63.0% of
the Black population), 54 African Black both parents born in
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Author Summary
Peptides from cellular proteins evoking alloimmune responses in
human leukocyte antigen–identical transplantation are called minor
histocompatibility (H) antigens. Upon hematopoietic stem cell
transplantation (HSCT) for hematological malignancies or for solid
tumors, responses to minor H antigens may have detrimental
effects, e.g., graft-versus-host-disease and graft rejection, but can
also significantly contribute to the eradication of the tumor cells. We
designated the latter antigens as ‘‘tumor’’ minor H antigens. Current
clinical trials aim at using these tumor minor H antigens to boost the
graft-versus-tumor response. So far, it is unclear how frequently the
HSCT recipient and donor differ in their minor H antigens and thus
how many cancer patients are eligible for minor H antigen-based
treatment. Therefore, worldwide 31 laboratories joined forces to
determine the genotype and phenotype frequencies of ten
autosomally encoded minor H antigens in six ethnic populations.
The frequencies vary depending upon ethnic background and
geographic location of the population, implying that the potential
applicability of the tumor minor H antigens differs from one
population to another. Depending on the population, the current
theoretical percentages of clinical application of the eight tumor
minor H antigens in HLA-matched combinations is estimated at 12%
to 34%.Africa (33.2%), three South or Central American Black
(1.9%), and three were Black not otherwise speciﬁed (1.9%).
The White population originated from Europe (82.1%),
Australia (0.6%), South Africa (0.5%), Southern America
(6.1%), and Northern America (10.7%). The group ‘‘others’’
comprised a major population of Cape Colored individuals
from South Africa (n¼65; 2.4% of the study population) and
a Mulatto population from Brazil (n¼23; 0.9%). Both groups
comprise individuals of mixed ethnicity.
Minor H Antigen Phenotype Frequencies
HA-1. The HLA-A2-restricted immunogenic HA-1 pheno-
type (i.e., HA-1
HH and HA-1
HR genotypes; see Table 1 for a
complete list of the immunogenic and nonimmunogenic
minor H alleles and Table 2 for their allele frequencies) is
most abundant in the Black population (73.7%; Table 3 and
Table S1), followed by the Asian/Paciﬁc population (71.2%)
and the Mexican Mestizos (69.6%). In the White and the
Cape Colored populations the frequency is substantially
lower (58.8% and 61.4%, respectively). The differences
between the White population compared to the Black,
Asian/Paciﬁc, or Mexican Mestizo populations reached
statistical signiﬁcance (p , 0.001, p , 0.001, and p , 0.025,
respectively).
HA-2. The HLA-A2-restricted immunogenic HA-2 pheno-
type frequency (i.e., HA-2
VV and HA-2
VM genotypes) has an
average of 95.2% and is equally high in all populations
studied (Table 3). The Brazilian Mulatto population has a
frequency (86.3%) signiﬁcantly lower than the Asian/Paciﬁc
(99.2%; p , 0.001), Black (97.5%; p , 0.025), and Mexican
Mestizo populations (97.3%; p , 0.025).
HA-3. The HLA-A1-restricted immunogenic HA-3 pheno-
type (i.e., HA-3
TT and HA-3
TM) has a high frequency in the
White (87.0%) and Mulatto populations (95.7%). The
frequency of HA-3 is signiﬁcantly lower (approximately
75%) in all other populations (White versus rest, p , 0.001;
Mulatto versus rest, p ¼ 0.05).
HA-8. The frequency of the HLA-A2-restricted immuno-
genic HA-8 phenotype (i.e., HA-8
RR and HA-8
RP) shows a
broad range of frequencies with 47.6% in the Cape Colored
population and 76.7% in the Mexican Mestizos.
HB-1. For HB-1, two immunogenic alleles (HB-1
H and HB-
1
Y) presented by the HLA-B44 molecule have been described
[24]. Phenotypes frequencies were therefore calculated for
both the HB-1
H and the HB-1
Y T-cell epitopes (see Table S1).
The frequency of the immunogenic HB-1
H phenotype (i.e.,
HB-1
HH and HB-1
HY genotypes) is 94.8% in the White
population, 96.8% in the Black population, 92.1% in the
Cape Colored population, and 87.0% in the Brazilian Mulatto
population. The differences between these populations are
not statistically signiﬁcant. When compared to the ﬁrst three
populations, the HB-1
H phenotype is signiﬁcantly different in
the Asian/Paciﬁc (89.6%, p , 0.001) and in the Mexican
Mestizo (75%, p , 0.001) populations. The HLA-B44-
restricted immunogenic HB-1
Y allele (i.e., HB-1
HY and HB-
1
YY genotypes) occurs in approximately 46% of the individ-
uals in the Asian/Paciﬁc, Black, White, and Cape Colored
populations. This phenotype is observed at a higher
frequency in the Mexican Mestizo (73.4%, p , 0.001) and
the Mulatto (60.9%, not signiﬁcant) populations.
ACC-1. The HLA-A24-restricted ACC-1 immunogenic
phenotype (i.e., ACC-1
YY and ACC-1
YC genotypes) is at
average observed in 48.5% of the analyzed individuals. The
Asian/Paciﬁc and the Cape Colored population have signiﬁ-
cantly higher frequencies with 66.0% (p , 0.001) and 64.1%
(p , 0.01), respectively, more than the Black, White, Mexican
Mestizo, and Mulatto populations.
ACC-2. The HLA-B44-restricted ACC-2 immunogenic
phenotype (i.e., ACC-1
DD and ACC-1
DG genotypes) frequency
shows a diverse distribution. In the Asian/Paciﬁc, White, and
Cape Colored population, the immunogenic phenotype has a
frequency of approximately 45%, while this frequency is only
30.4% in the Brazilian Mulattos (not signiﬁcant), 13.0% in the
Black population (p , 0.001), and 23.2% in the Mexican
Mestizo population (not signiﬁcant).
SP110. The HLA-A3-restricted SP110 immunogenic phe-
notype (i.e., SP110
RR and SP110
RG genotypes) displays a very
high frequency in the non-White populations (90%–100%),
which is signiﬁcantly lower in the White population (85.3%, p
, 0.001).
PANE1. The HLA-A3-restricted PANE1 immunogenic
phenotype (i.e., PANE1
RR and PANE1
R* genotypes) has
Table 1. Overview of the Characteristics of Ten Minor H Antigens Investigated in this Study
Minor H
Antigen
HLA-Restriction Gene Chromosomal
Location
dbSNP
Reference ID
Immunogenic
Allele
Nonimmunogenic
Allele
Immunogenic
Phenotypes
HA-1 HLA-A2/B60 HMHA1 19p13.3 rs1801284 H R HH and HR
HA-2 HLA-A2 MYO1G 7p13–p11.2 — V M VV and VM
HA-3 HLA-A1 AKAP13 15q24-q25 rs7162168 T M TT and TM
HA-8 HLA-A2 KIAA0020 9p24.2 rs2173904 R P RR and RP
HB-1 HLA-B44 HMHB1 5q32 rs161557 H, Y
a HH and HY
YY and HY
ACC-1 HLA-A24 BCL2A1 15q24.3 rs1138357 Y C YY and YC
ACC-2 HLA-B44 BCL2A1 15q24.3 rs3826007 D G DD and DG
SP110 HLA-A3 SP110 2q37.1 rs1365776 R G RR and RG
PANE1 HLA-A3 CENPM 22q13.2 — R * RR and R*
UGT2B17 HLA-A29 UGT2B17 4q13 — þ 
b þ
Immunogenic and nonimmunogenic alleles are indicated by their polymorphic amino acid in one-letter code.
aBoth the HB-1
H and the HB-1
Y allele are immunogenic.
bThe nonimmunogenic allele of UGT2B17 is lacking.
doi:10.1371/journal.pgen.0030103.t001
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Minor H Antigen Phenotype Frequenciesfrequencies in almost all populations of 90%–100%. The
most signiﬁcant deviation was observed in the Mulatto
population with 77.3% (p , 0.01).
UGT2B17. The gene encoding UGT2B17 has only one
functional allele; its allelic counterpart is deleted. Therefore,
the immunogenic phenotype is deﬁned as the presence of the
gene on at least one of the two Chromosomes 4. Con-
sequently, the heterozygote genotype of the HLA-A29-
restricted UGT2B17 is not detectable. The immunogenic
phenotype can be observed at high frequency in the White
population (96.5%). In the Asian/Paciﬁc, Black (70.9), and
Mexican Mestizo (62.4%) populations, the frequency is
signiﬁcantly lower (p , 0.001). The frequency in the Cape
Colored population is even lower (47.2%, Asian/Paciﬁc, Black,
and Mexican Mestizo versus Cape colored: p , 0.001). The
lowest frequency is displayed by the Mulatto population
(22.0%, Cape Colored versus Mulatto: p , 0.01).
Linkage Analysis of the ACC-1 and ACC-2 Alleles
Linkage analyses of the ACC-1/ACC-2 haplotypes in Whites
who are homozygous for ACC-1 and/or ACC-2, yield a
correlation coefﬁcient r
2 of 0.91 between the alleles of
ACC-1 and ACC-2, indicating the existence of immunogenic
and nonimmunogenic ACC-1/ACC-2 haplotypes (Table 4). In
the other ethnic populations, the correlation is much weaker,
and clearly absent in the Black population (r
2 ¼ 0.18).
Geospatial Analysis of White Minor H Antigen Frequencies
Due to the density of the number of geographical locations
and of individuals from the identical ethnic background per
location, reliable geospatial analysis could only be executed
on the White population.
HA-1. Geospatial analysis was performed on the HA-1
immunogenic phenotype frequencies within the White
population. As shown in Figure 1A, no correlation between
the HA-1 phenotype frequency and the geographic local-
ization can be observed within Europe.
HA-2. A large geospatial diversity in HA-2 phenotype
frequencies is observed among Whites grouped by location,
ranging from approximately 70% positive for the immuno-
genic phenotype in Whites from Seattle and Baltimore to
95% in the British, Irish, Dutch, German, and Polish samples
(unpublished data). However, no clear geographic pattern is
observed within the European White population (Figure S1B).
HA-3. The phenotype frequencies of HA-3 within the
White population do not display a geographical pattern.
HA-8. Geospatial analysis of the HA-8 phenotype frequen-
cies strongly indicates the presence of a north–south
gradient, with phenotype frequencies of more than 65% in
The Netherlands, Germany, and Finland, approximately 60%
in Central Europe, Croatia and Poland, and Northern Italy,
and less than 55% in Turkey and Southern Italy (Figure 1B).
HB-1. The phenotype frequencies of HB-1
H (Figure S1E) and
HB-1
Y (unpublished data) are very diverse. No geographical
pattern can be detected for the HB-1 minor H antigens.
ACC-1 and ACC-2. Due to the strong linkage between the
alleles of ACC-1 and ACC-2 in the White population (Table
4), the geospatial analyses of these two minor H antigens yield
nearly identical patterns (Figure 1C and Figure S1F). The
results suggest a higher frequency of the immunogenic
phenotypes in the central part of Europe, but a clear
geographical pattern cannot be detected.
SP110. The SP110 phenotype frequencies within the White
population show diversity when geospatially analyzed (Figure
S1H). However, no distinct pattern can be observed.
PANE1. The phenotype frequencies of PANE1 of the
various White populations do not display a geographical
pattern.
Table 2. Frequencies of the Alleles of Ten Autosomally Encoded Minor H Antigens in Six Different Ethnic Populations
Asian/ Pacific
(n ¼ 305)
Black
(n ¼ 162)
White
(n ¼ 2011)
Mexican Mestizo
(n ¼ 119)
Cape Colored
(n ¼ 65)
Mulatto
(n ¼ 23)
Total
(n ¼ 2685)
HA-1 H 47.6% 47.8% 35.9% 41.4% 35.2% 41.7% 37.9%
R 52.4% 52.2% 64.1% 58.6% 64.8% 58.3% 62.1%
HA-2 V 91.9% 83.6% 75.6% 83.5% 84.9% 70.5% 78.1%
M 8.1% 16.4% 24.4% 16.5% 15.1% 29.5% 21.9%
HA-3 T 57.4% 58.6% 65.2% 54.9% 55.6% 60.9% 63.3%
M 42.6% 41.4% 34.8% 45.1% 44.4% 39.1% 36.7%
HA-8 R 39.7% 35.8% 45.0% 50.8% 29.4% 32.6% 43.7%
P 60.3% 64.2% 55.0% 49.2% 70.6% 67.4% 56.3%
HB-1 H 69.9% 75.6% 74.2% 50.9% 73.0% 63.0% 72.8%
Y 30.1% 24.4% 25.8% 49.1% 27.0% 37.0% 27.2%
ACC-1 Y 42.5% 26.1% 26.8% 26.5% 36.7% 23.9% 28.4%
C 57.5% 73.9% 73.2% 73.5% 63.3% 76.1% 71.6%
ACC-2 D 28.9% 6.5% 25.5% 11.6% 24.2% 15.2% 23.9%
G 71.1% 93.5% 74.5% 88.4% 75.8% 84.8% 76.1%
SP110 R 76.0% 91.6% 61.2% 80.3% 74.2% 87.0% 65.7%
G 24.0% 8.4% 38.8% 19.7% 25.8% 13.0% 34.3%
PANE1 R 71.2% 94.7% 69.9% 82.5% 83.6% 63.6% 72.4%
* 24.0% 8.4% 38.8% 19.7% 25.8% 13.0% 34.3%
UGT2B17 þ 44.9% 46.0% 81.3% 38.7% 24.3% 11.7% 61.6%
  55.1% 54.0% 18.7% 61.3% 75.7% 88.3% 38.4%
Immunogenic and nonimmunogenic alleles are indicated by their polymorphic amino acid in one-letter code. For UGT2B17 a ‘‘þ’’ indicates the immunogenic allele and a ‘‘ ’’ indicates the
nonimmunogenic allele. Allele frequencies of UGT2B17 were estimated using the phenotype frequencies.
doi:10.1371/journal.pgen.0030103.t002
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Minor H Antigen Phenotype FrequenciesUGT2B17. Almost all individuals within the White pop-
ulation express the UGT2B17 immunogenic phenotype
(96.5%), while the nonimmunogenic phenotype is nearly
absent (3.5%). With frequencies of 90%–100% in Western
Europe and less than 65% in the eastern parts, the
immunogenic phenotype clearly decreases in the eastward
direction (Figure 1D). Although data from the Asian/Paciﬁc
population are limited to two subpopulations, i.e., the Asian
Indian population two locations) and the South East Asian
population from Taiwan and Japan, they indicate that the
immunogenic UGT2B17 phenotype further decreases in the
eastward direction (Asian Indian population 58.7%, South
East Asian population 33.3%), suggesting the presence of a
more global east–west gradient in Eurasia.
Estimation of Minor H Antigen Disparity Rates among
HLA-Matched Related and Unrelated Individuals
The information on the phenotype frequencies subse-
quently allows calculation of the chance of having a minor H
antigen disparate donor/recipient pair in the HLA-matched
related (sib) and unrelated (matched unrelated donor, MUD)
SCT settings. Frequencies of HLA molecules also vary among
the ethnic populations (http://www.allelefrequencies.net).
Consequently, the theoretical estimations of the minor H
antigen phenotypic disparities in HLA-matched pairs are
corrected for the frequency of the relevant HLA restriction
molecule in each ethnic population.
HA-1. In the White population the estimated disparity
rates for the HLA-A2-restricted minor H antigen HA-1, and
thus corrected for the frequency of HLA-A2 in the White
population, are 6.6% for sib pairs (Table 5) and 12.0% for
MUD pairs (Table 6). Disparity rates in the Mexican Mestizo
and Mulatto populations were slightly higher. Lower disparity
rates are estimated for the Asian/Paciﬁc and the Black
populations, due to differences in both the frequency of the
immunogenic HA-1 phenotype and the HLA-A2 molecule.
Table 3: Genotype Frequencies of Ten Autosomally Encoded Minor H Antigens in Six Different Ethnic Populations
Asian/ Pacific
(n ¼ 242)
Black
(n ¼ 162)
White
(n ¼ 2011)
Mexican Mestizo
(n ¼ 119)
Cape Colored
(n ¼ 65)
Mulatto
(n ¼ 23)
Total
(n ¼ 2685)
HA-1 HH 24.0% 21.8% 13.0% 12.9% 7.8% 16.7% 14.4%
HR 47.2% 51.9% 45.8% 56.9% 54.7% 50.0% 47.0%
RR 28.8% 26.3% 41.2% 30.2% 37.5% 33.3% 38.6%
HA-2 VV 84.6% 69.8% 56.8% 69.6% 73.0% 54.5% 61.1%
VM 14.6% 27.8% 37.7% 27.7% 23.8% 31.8% 34.1%
MM 0.8% 2.5% 5.5% 2.7% 3.2% 13.6% 4.8%
HA-3 TT 38.0% 38.9% 43.3% 31.3% 36.5% 26.1% 41.7%
TM 38.8% 39.5% 43.7% 47.3% 38.1% 69.6% 43.3%
MM 23.2% 21.6% 13.0% 21.4% 25.4% 4.3% 15.0%
HA-8 RR 16.1% 11.7% 19.7% 25.0% 11.1% 8.7% 18.8%
RP 47.1% 48.1% 50.4% 51.7% 36.5% 47.8% 49.7%
PP 36.8% 40.1% 29.8% 23.3% 52.4% 43.5% 31.5%
HB-1 HH 50.2% 54.4% 53.7% 26.6% 54.0% 39.1% 52.1%
HY 39.4% 42.4% 41.2% 48.6% 38.1% 47.8% 41.4%
YY 10.4% 3.2% 5.2% 24.8% 7.9% 13.0% 6.5%
ACC-1 YY 19.1% 9.4% 7.0% 6.7% 9.4% 8.7% 8.3%
YC 46.9% 33.3% 39.6% 39.5% 54.7% 30.4% 40.2%
CC 34.0% 57.2% 53.5% 53.8% 35.9% 60.9% 51.5%
ACC-2 DD 7.0% 0.0% 6.4% 0.0% 6.3% 0.0% 5.7%
DG 43.8% 13.0% 38.1% 23.2% 35.9% 30.4% 36.3%
GG 49.2% 87.0% 55.5% 76.8% 57.8% 69.6% 57.9%
SP110 RR 60.3% 84.4% 37.0% 65.8% 53.1% 73.9% 43.9%
RG 31.5% 14.4% 48.3% 28.9% 42.2% 26.1% 43.6%
GG 8.2% 1.3% 14.7% 5.3% 4.7% 0.0% 12.5%
PANE1 RR 49.0% 90.7% 47.2% 68.3% 70.3% 50.0% 51.6%
R* 44.4% 8.1% 45.3% 28.3% 26.6% 27.3% 41.6%
** 6.6% 1.2% 7.4% 3.3% 3.1% 22.7% 6.8%
UGT2B17 þ/þ 20.1% 21.2% 66.1% 15.0% 5.9% 1.4% 38.0%
þ/  49.5% 49.7% 30.4% 47.4% 36.8% 20.6% 47.3%
 /  30.4% 29.1% 3.5% 37.6% 57.3% 78.0% 14.7%
For each minor H antigen, the first two listed genotypes are immunogenic, while the third is the homozygous nonimmunogenic genotype. Genotype frequencies of UGT2B17 were
estimated as described in the Materials and Methods section.
doi:10.1371/journal.pgen.0030103.t003
Table 4. Analysis of ACC-1/ACC-2 Haplotypes
ACC-1 ACC-2 Asian/
Pacific
Black White Mexican
Mestizo
Other
Y D 25.6% 6.1% 23.9% 12.1% 24.0%
Y G 17.6% 19.9% 1.4% 11.5% 10.2%
C D 1.0% — 0.4% — 0.7%
C G 56.4% 74.0% 74.3% 76.4% 65.1%
r
2 0.43 0.18 0.91 0.445 0.578
Haplotypes were constructed using genotyping data from individuals homozygous for
either ACC-1 or ACC-2. The immunogenic alleles are underlined. Correlation coefficients
(r
2) were estimated using the Chaplin software.
doi:10.1371/journal.pgen.0030103.t004
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Minor H Antigen Phenotype FrequenciesHA-2. Due to the high frequency of the immunogenic HA-2
phenotype in all populations, the estimated theoretical
disparity rates for HA-2, corrected for the HLA-A2 frequen-
cies, are low (sib pairs 0.2%–2.2%, MUD pairs 0.3%–6.3%;
Tables 5 and 6). In the Asian/Paciﬁc population HA-2
disparity is nearly absent (0.2% in sib pairs and 0.3% in
MUD pairs). Signiﬁcant immunological disparity for HA-2 is
restricted to the White (2.6%) and Mulatto (6.3%) in MUD
pairs.
HA-3. Based upon the frequency data of the HA-3
immunogenic phenotype and the HLA-A1 frequencies, HA-
3 disparity in sib pairs is below 2% in all populations (Table
7). Highest disparity rates are estimated for MUD pairs in the
Black (2.1%), the White (3.4%), and the Mexican Mestizo
(2.9%) populations (Table 8).
HA-8. The disparity rates for the HLA-A2-restricted HA-8
are the lowest in the Black population with 4.9% in sib pairs
and 8.4% in MUD pairs (Tables 7 and 8), and the highest in
the Mulatto population (sib pairs: 7.9%; MUD pairs: 13.2%).
All other ethnic populations display comparable disparity
rates (sib pairs: 6.1%–7.9%; MUD pairs: 10.0%–10.4%).
HB-1. The estimated disparity in the White and the Mulatto
population for the HLA-B44-restricted HB-1
H is 1.2% and
1.4%, respectively, in the sib pairs and 1.4% and 2.2% in the
MUD pairs, respectively. For all populations, the disparity
rate for the HLA-B44-restricted HB-1
Y is higher than the
rates for HB-1
H disparity (sib pairs: 0.5%–4.1%; MUD pairs:
1.0%–7.2%). The combined calculation on disparity rates for
the bidirectional immunogenic HB-1 phenotypes, i.e., HB-1
H
and the HB-1
Y, predicts the highest HB-1 disparity in the
White population (sib pairs: 5.2%; MUD pairs: 8.5%) and in
the Mulatto population (sib pairs: 4.0%; MUD pairs: 6.6%).
ACC-1. The estimated disparity rates for the HLA-A24-
restricted ACC-1 in all populations were between 0.4%–6.5%
in sib pairs and between 0.9%–12.1% for MUD pairs. This
relatively broad range is caused by the highly variable
frequency of HLA-A24, which is over 50% in the Asian/
Paciﬁc populations and less than 5% in the Black population.
ACC-2. Disparity for the HLA-B44-restricted ACC-2 minor
H antigen is low in the Black and Mexican Mestizo population
(sib pairs and MUD pairs: ,1.0%) Highest disparity rates
were estimated for the Caucasian population (sib pairs: 3.8%;
MUD pairs: 7.1%).
SP110. SP110 disparity is nearly absent in the Asian/Paciﬁc
population (sib pairs: 0.0%; MUD pairs: 0.1%), the Black
population (sib pairs: 0.0%; MUD pairs: 0.1%), the Mexican
Mestizo population (sib pairs: 0.1%; MUD pairs: 0.2%), and in
the Mulatto population (sib pairs: 0.1%; MUD pairs: 0.0%).
Highest disparity was estimated for the White pairs (sib pairs:
2.1%; MUD pairs: 3.3%).
PANE1. Disparity for the HLA-A3-restricted minor H
antigen PANE1 above 1% has only been estimated for sib and
MUD pairs of White origin (2.1% and 1.8%, respectively) and
for MUD pairs of Mulatto origin (1.7%; Table 6).
UGT2B17. Since the frequency of individuals homozygous
for the UGT2B17 gene deletion genotype is low in the White
population and the HLA-A29 restriction molecule is infre-
quent in this population (7.5%), the estimated disparity rates
Figure 1. Geospatial Analyses of the Phenotype Frequencies of HA-1 (A), HA-8 (B), ACC-2 (C), and UGT2B17 (D) in the European White Populations
Red dots represent the centers from which the frequency data were obtained. Numbers in the scaling indicate the proportion of individuals with an
immunogenic phenotype.
doi:10.1371/journal.pgen.0030103.g001
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Minor H Antigen Phenotype Frequenciesfor White sib and MUD pairs are low (sib pairs: 0.2%; MUD
pairs: 0.3%). The combination of a higher frequency of
homozygous UGT2B17 gene deletion and the HLA-A29
restriction molecule (12.5%) in the Black population results
in 1.5% estimated disparity in sib pairs and 2.6% in MUD
pairs. In all other populations, the disparity rates are below
1.5% (Tables 7 and 8).
Discussion
The present global study demonstrates the genotype and
phenotype frequencies of all ten autosomally encoded minor
H antigens identiﬁed at the initiation of the study, in 2,685
individuals of six different ethnic populations. Based on this
information, the geospatial frequency distribution of the
currently known minor H antigens is also described. More-
over, the phenotype frequencies provide for the ﬁrst time a
theoretical estimation for the relevance of ten minor H
antigens for their potential use in minor H antigen–based
immunotherapeutic protocols in SCT.
Small but signiﬁcant differences in the genotype and
phenotype frequencies in the various ethnic populations
were observed for all autosomally encoded minor H antigens.
The highest variation among the ethnic populations was
observed for UGT2B17 (Figure 2C). The UGT2B17 frequency
data in the White population are in line with previous studies
[22]. As mentioned earlier, the UGT2B17 immunogenic
phenotype results from homozygous deletion of the entire
UGT2B17 gene. Interestingly, homozygous UGT2B17 gene
deletion seems to be tolerated differently in the various
ethnic populations.
In the present study, we also addressed the issue of linked
alleles by analyzing ACC-1 and/or ACC-2 homozygous
individuals. The two SNPs responsible for the ACC-1 and
ACC-2 minor H antigens are both located on the BCL2A1
gene [25]. The distance between these two SNPs is only 189
bp. Cellular recognition assays indicated that, within the
White population from the Centre d’Etude du Polymor-
phisme Humain, the immunogenic alleles of ACC-1 and ACC-
2 are linked [26]. The same study, however, also reported on
Japanese individuals positive for only one of the two minor H
antigens, thus providing evidence that the ACC-1 and ACC-2
are deﬁned by distinct SNPs, which was conﬁrmed by the
characterization of the two relevant minor H peptides. In the
White population, a strong linkage between the two alleles of
ACC-1 and ACC-2 was indeed observed (Table 4). However, in
Table 5. Estimated Disparity Rates for Hematopoietic Minor H Antigens in HLA-Matched Transplant Sib Pairs Corrected for the
Frequencies of the HLA Restriction Molecule
Asian/ Pacific
(n ¼ 305)
Black
(n ¼ 162)
White
(n ¼ 2011)
Mexican Mestizo
(n ¼ 119)
Mulatto
(n ¼ 23)
HA-1 4.7% 4.2% 6.6% 8.5% 7.0%
HA-2 0.2% 0.6% 1.8% 1.0% 2.2%
HB-1
H 0.5% 0.4% 1.2% 0.5% 1.4%
HB-1
Y 1.4% 1.4% 4.1% 0.5% 2.6%
ACC-1 6.5% 0.4% 2.2% 3.3% 2.1%
ACC-2 1.6% 0.6% 3.8% 0.5% 2.4%
SP110 0.0% 0.0% 2.1% 0.1% 0.1%
PANE1 0.1% 0.0% 1.5% 0.1% 0.4%
At least one mismatch 14.3% 7.4% 21.2% 13.9% 17.0%
HLA frequency data were obtained from http://www.allelefrequencies.net. The chance for at least one minor H antigen mismatch in the donor to recipient direction was estimated as 1 
((1   p
HA-1)( 1  p
HA-2)( 1  p
HB-1H)( 1  p
HB-1Y)( 1  p
ACC1)( 1  p
ACC2)( 1  p
SP110)( 1  p
PANE1)), where p
HA-1 is the disparity rate for HA-1, p
HA-2 for HA-2, etc., as listed in this table.
doi:10.1371/journal.pgen.0030103.t005
Table 6. Estimated Disparity Rates for Hematopoietic Minor H Antigens in MUD Transplant Pairs Corrected for the Frequencies of the
HLA Restriction Molecule
Asian/ Pacific
(n ¼ 305)
Black
(n ¼ 162)
White
(n ¼ 2011)
Mexican Mestizo
(n ¼ 119)
Mulatto
(n ¼ 23)
HA-1 8.8% 6.8% 12.0% 12.2% 11.9%
HA-2 0.3% 0.8% 2.6% 1.5% 6.3%
HB-1
H 1.0% 0.3% 1.4% 0.9% 2.2%
HB-1
Y 2.7% 2.3% 7.2% 1.0% 4.6%
ACC-1 12.1% 0.9% 4.0% 6.1% 4.6%
ACC-2 2.7% 1.0% 7.1% 0.9% 4.1%
SP110 0.1% 0.1% 3.3% 0.2% 0.0%
PANE1 0.1% 0.1% 1.8% 0.1% 1.7%
At least one mismatch 25.3% 11.9% 33.6% 21.3% 30.7%
Analyses and calculations were performed as described in the legend of Table 5.
doi:10.1371/journal.pgen.0030103.t006
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Minor H Antigen Phenotype Frequenciesthe other ethnic populations, haplotypes containing an
immunogenic allele for one and a nonimmunogenic allele
for the other BCL2A1 polymorphism occur relatively fre-
quently. These observations have important implications for
minor H antigen typing, particularly in non-White individ-
uals, where genotyping for both the ACC-1 and the ACC-2
minor H antigen may be essential.
The availability of the large dataset on the phenotype
frequencies of ten minor H antigens in the White population
(2,011 White individuals from 22 different geographical
locations) allowed for the performance of geospatial analyses.
Geographical correlations were observed for HA-8 and
UGT2B17. A distinct north–south gradient for the minor H
antigen HA-8 was found, with high frequencies for the
immunogenic phenotype in the northern parts of Europe and
lower frequencies in the Mediterranean regions. It would be
of interest to speciﬁcally analyze more samples from both the
Scandinavian and the Mediterranean region to further
conﬁrm these observations. North-to-south gradients have
been suggested to be a more general phenomenon for SNPs.
A recent study demonstrated clustering of northern and
southern European populations via SNP analyses [27].
However, since none of the other SNP-based minor H
antigens demonstrated a north-to-south frequency gradient,
we cannot conﬁrm this suggestion.
The geospatial analyses of the White population on the
European continent indicate a strong west-to-east correlation
between the geographic location and the phenotype fre-
quency of UGT2B17. With 58.7% in India, 32.1% in Taiwan,
and 30.0% in Japan, the current Asian dataset suggests that
the west-to-east gradient of UGT2B17 extends further east-
wards in Eurasia. Additional data from regions such as
E a s t e r nE u r o p ea n dt h eM i d d l eE a s ta r er e q u i r e dt o
strengthen this supposition.
Apart from HA-8 and UGT2B17, no geographical correla-
tion could be detected for the other eight minor H antigen
phenotype frequencies. A previous study analyzing geospatial
distribution observed a north-to-south gradient for HA-1
within Europe [28]. The data included in the latter meta-
analysis match our data and our extrapolation to Spain and
Greece. Indeed, if only samples from the same regions
(countries: The Netherlands, Germany, and Italy) had been
analyzed using our data, a similar conclusion could have been
drawn. However, we observed a large variation in the
frequency of the immunogenic HA-1 phenotype in central
Europe, leading to an absence of a clear north–south gradient
for HA-1 in our study. The limited number of locations and
the fact that these locations were oriented along a north-to-
south axis, thereby skewing the results towards a similar
orientation of the gradient, may have inﬂuenced the
conclusions of Di Terlizzi, et al. [28].
Minor H antigens are peptides arising from genomic
polymorphisms. Interestingly, most minor H antigens display
a unidirectional immune recognition pattern, where the one
allele is immunogenic and the other nonimmunogenic.
Various mechanisms have been reported to be responsible
for this phenomenon of ‘‘one allele immunogenicity.’’ One of
these mechanisms described is via differential antigen
processing of HA-3 by the proteasome [29] or by TAP
translocation of HA-8 [30]. The lack of a nonimmunogenic
counterpart can also have a genetic basis. These cases involve
mechanisms such as gene deletion of UGT2B17 [31], frame-
Table 7. Estimated Disparity Rates for Broadly Expressed Minor H Antigens in HLA-Matched Transplant Sib Pairs Corrected for the
Frequencies of the HLA Restriction Molecule
Asian/ Pacific
(n ¼ 305)
Black
(n ¼ 162)
White
(n ¼ 2011)
Mestizo
(n ¼ 119)
Mulatto
(n ¼ 23)
HA-3 0.1% 0.9% 1.9% 1.6% 1.8%
HA-8 5.5% 4.9% 6.1% 6.4% 7.9%
UGT2B17 0.2% 1.5% 0.2% 0.6% 0.5%
At least one mismatch 5.8% 7.2% 8.1% 8.5% 10.0%
HLA frequency data were obtained from http://www.allelefrequencies.net. The chance for at least one minor H antigen mismatch in the donor to recipient direction was estimated as 1 
((1   p
HA  3)(1   p
HA-8)( 1  p
UGT2B17)), where p
HA-3 is the disparity rate for HA-3, p
HA-8 for HA-8, and p
UGT2B17 for UGT2B17 as listed in this table.
doi:10.1371/journal.pgen.0030103.t007
Table 8. Estimated Disparity Rates for Broadly Expressed Minor H Antigens in MUD Transplant Sib Pairs Corrected for the Frequencies
of the HLA Restriction Molecule
Asian/ Pacific
(n ¼ 305)
Black
(n ¼ 162)
White
(n ¼ 2011)
Mestizo
(n ¼ 119)
Mulatto
(n ¼ 23)
HA-3 0.3% 2.1% 3.4% 2.9% 0.7%
HA-8 10.0% 8.4% 10.3% 10.4% 13.2%
UGT2B17 0.3% 2.6% 0.3% 1.2% 1.0%
At least one mismatch 10.5% 12.6% 13.6% 14.0% 14.7%
Analyses and calculations were performed as described in the legend of Table 7.
doi:10.1371/journal.pgen.0030103.t008
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Minor H Antigen Phenotype Frequenciesshift due to nucleotide insertion for LRH-1 [32], and
introduction of a translation termination codon for PANE1
and ECGF1 [12,33]. As discussed above, the minor H antigen
alloimmune responses are generally unidirectional. Conse-
quently, the immune responses between minor H antigen
disparate HLA-matched sibs and MUD pairs are similarly
unidirectional.
The obtained information on the global phenotype
frequencies of the minor H antigens known to date allows
estimations on the disparity rates between putative HLA-
matched stem cell donor and recipient pairs. The clinical
relevance of minor H antigens currently lies in their curative
effect following SCT. Minor H antigens qualifying for usage
in the GvT effect of SCT are those with well-deﬁned
restricted cell and tissue expression. Earlier, dissection of
minor H antigens into broadly expressed and expression
restricted to the hematopoietic system has been described [7].
Interestingly, the hematopoietic minor H antigens HA-1 and
ACC-1/ACC-2 show additional expression on carcinomas [9–
11]. The calculations of the current clinically relevant minor
H antigens are thus based on both their unidirectional
immunogenicity and their hematopoietic—and in case of
HA-1 and ACC-1/ACC-2, hematopoietic and solid tumor—
expression proﬁles. The minor H antigen disparity rate
calculations require additional correction of the HLA
restriction molecules that are also differentially distributed
among the various ethnic populations. For correct estima-
tions of the current minor H antigen clinical potential, all of
the above characteristics have been taken into account. The
results can be summarized as follows. The high phenotype
frequency of HLA-A2, in combination with a relatively high
disparity rate for HA-1 in all ethnic populations studied,
currently marks HA-1 as the most favorable minor H antigen
for clinical application in all ethnic populations. Similar
results, although limited to only one or two ethnic groups,
were obtained for the minor H antigens ACC-1, ACC-2, and
HB-1
Y. The ACC-1 minor H antigen is restricted to the Asian/
Paciﬁc population, with 6.5% disparity in sib pairs and 12.1%
in MUD pairs. Similarly, ACC-2 can only be applied in a
signiﬁcant proportion of the pairs in the White and Mulatto
population, as counts for HB-1
Y. Finally, estimating the
chance of having at least one mismatch for a hematopoietic
system–restricted minor H antigen out of the eight hema-
topoietic minor H antigens studied herein, revealed 21.2%
and 33.6% for White sib and MUD pairs respectively, and
7.4% and 11.9% for the Black population, respectively. In all
of these estimations, the HLA allele frequencies of the
respective populations were taken into account.
The estimations of the minor H antigen disparity rates
between HLA-matched pairs strongly differ among the
various ethnic populations, raising the question of whether
some populations display more phenotypic diversity than
others. To address this issue, we subjected the mean genetic
disparity rates per population to a paired t-test. The overall
genetic disparity is lowest in the Black population (Figure 2).
It remains unclear which mechanism forms the basis for this
phenomenon. The Black population analyzed in this study
comprised two major subpopulations, i.e., the African Black
and the African American population. In contrast with the
African Black population, the African American population
has considerable Caucasoid admixture (E. D. du Toit,
personal communication). We therefore performed a sepa-
Figure 2. Estimated Minor H Antigen Disparity Rates
Comparison for sib (A) and MUD (B) transplantations among six different
ethnic populations. Data are depicted as the mean disparity rate of the
ten analyzed minor H antigens and the standard error. (C) Variation in
frequencies of the immunogenic minor H antigen phenotype per minor
H antigen.
doi:10.1371/journal.pgen.0030103.g002
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Minor H Antigen Phenotype Frequenciesrate analysis of the minor H antigen phenotype frequencies
in these two subpopulations for all minor H antigens.
Although a tendency towards White minor H antigen
phenotype frequencies was observed for the African Amer-
ican population, the differences didn’t reach statistical
signiﬁcance (unpublished data). Similarly, a subanalysis of
the Asian/Paciﬁc population yielded no major regional
differences except for the UGT2B17 minor H antigen
(unpublished data).
The clinical potential of the current set of identiﬁed minor
H antigens is clearly limited and points to enlargement of the
pool of clinically relevant minor H antigens. Reverse
immunology has recently been applied for identifying new
minor H antigens [34]. This approach uses computer
algorithms such as SYFPEITHI [35] and Bimas [36] to predict
binding of polymorphic peptides to the HLA allele of choice.
Accordingly, the UGT2B17 gene could be analyzed for new
minor H peptides binding to frequently occurring HLA
alleles in the various ethnic populations (Table S2). Similar
analyses could be executed for HB-1
H for its relevance in the
Mexican Mestizo population, and HA-2 and PANE1 in the
Brazilian Mulatto population. Finally, to enlarge the pool of
minor H antigens potentially applicable in a stem cell–based
protocol for solid tumors, the reverse immunology approach
can be helpful in searching for minor H antigens with
restricted expression on carcinoma cells [9–11]. Here, the
search is speciﬁcally focused on SNPs in genes involved in
tumorigenesis [5].
In conclusion, we here report differences in minor H
antigen genotype and phenotype frequencies among and
within the major ethnic populations. Some of these differ-
ences are geographically correlated, while others seem to be
more randomly distributed. Moreover, the potential clinical
application of hematopoietic speciﬁc minor H antigens as
immunotherapeutic tools in SCT for hematological malig-
nancies was estimated. The theoretical chance of having a
difference for at least one hematopoietic minor H antigen in
the whole study group, thus corrected for the HLA
frequencies, is 11.9% to 33.6% in HLA-matched unrelated
pairs.
Materials and Methods
Sample selection and population description. The study population
consisted of 2,685 locally available randomly selected healthy subjects
and transplant donors. All research samples and data were collected
according to the subjects’ guidelines and protocols of the local
institutional review boards. Individuals with an unknown ethnical
background were excluded from the analyses.
Minor H antigen typing. DNA was isolated using the local standard
procedures used for HLA typing. Genotyping of ten autosomally
encoded minor H antigens and of HY was performed using the PCR-
SSP technique (Invitrogen, http://www.invitrogen.com). The details of
the minor H antigen typing methodology have been described before
[37]. Previously typed cells from the Centre d’Etude du Polymor-
phisme Humain-Human Genome Diversity Project Cell Line Panel
(CEPH panel) and from the reference DNA samples from the
University of California, Los Angeles, International DNA Exchange
Program were used as controls. All PCR-SSP samples were analyzed
on agarose gel. If the internal control PCRs failed for one of the two
allele of a particular minor H antigen, the typing for that minor H
antigen was marked as incomplete and data were excluded from the
analyses. The alleles of each minor H antigen were reported as the
amino acid resulting from the relevant SNP. Typing data and sample
parameters were submitted to a central online database (http://www.
lumc.nl/ihiw14).
Statistical analyses. Typing data were analyzed at three levels: (1)
the allele frequency, (2) genotype frequency, and (3) phenotype
frequencies. Allele and genotype frequencies except those of
UGT2B17 were calculated by direct counting. Since the minor H
antigen UGTB17 is the result of gene deletion, the applied method-
ology did not allow detection of UGT2B17 heterozygosity. Therefore
the UGT2B17 allele frequencies were estimated as
ﬃﬃﬃﬃﬃ
aa
p
for the
nonimmunogenic allele and 1  
ﬃﬃﬃﬃﬃ
aa
p
for the immunogenic allele,
where ‘‘aa’’ is the frequency of the nonimmunogenic phenotype. The
heterozygosity frequencies (Aa) for this minor H antigen were
estimated by 2 3 (1  
ﬃﬃﬃﬃﬃ
aa
p
) 3 (
ﬃﬃﬃﬃﬃ
aa
p
), assuming a Hardy-Weinberg
equilibrium.
Observed genotype frequencies were tested against Hardy-Wein-
berg equilibrium. The phenotype frequencies have been deduced
from the genotype frequencies. Individuals who were homozygous or
heterozygous positive for the immunogenic allele were regarded as
phenotypically positive. Individuals carrying two nonimmunogenic
alleles were marked as phenotypically negative. Since the HB-1
minor H antigen has been demonstrated to be immunogenic in
either direction, phenotype frequencies have been calculated
separately for the HB-1
H and the HB-1
Y allele as immunogenic
alleles. The statistical signiﬁcance of differences in allele, genotype,
and phenotype frequencies between the various populations and
geographic regions were determined by Chi-square analysis. The
SPSS statistical software system (SPSS 11.0, http://www.spss.com) was
used for these analyses. p-values lower than 0.05 were considered
statistically signiﬁcant.
Linkage of the alleles of ACC-1 and ACC-2 was analyzed with the
case-control haplotype inference (Chaplin) software [34]. Individuals
who were heterozygous for both ACC-1 and ACC-2 were classiﬁed as
noninformative and excluded from the analysis.
Estimations of the minor H antigen disparity rates. The disparity
rate is deﬁned as the chance of a putative transplant recipient with a
minor H antigen immunogenic phenotype having an HLA-identical
related or HLA-matched unrelated stem cell donor being homo-
zygous for the nonimmunogenic allele of the same minor H antigen
encoding gene. In the case of a putative HLA-matched unrelated
donor selection, the disparity rate is the frequency of homozygous
immunogenic (AA) and heterozygous (Aa) individuals multiplied by
the frequency of homozygous nonimmunogenic individuals (aa): ((AA)
þ(Aa))3(aa). Sib transplantation disparity rates were estimated by 3/
16(Aa)
2 þ 1/2(Aa)(aa). For both related and unrelated situations, the
rates were multiplied by the phenotype frequency of the relevant
HLA restriction molecule. To investigate the level of disparity within
each population, two-tailed Wilcoxon signed rank tests were
performed.
Spatial frequency distribution analysis. Spatial frequency distribu-
tion maps for each of the immunogenic minor H antigen phenotype
frequencies were constructed for the White population samples using
the Kriging procedure [38] with the Surfer 8 software (Golden
Software, http://www.goldensoftware.com). For these analyses the
geographical area between 29.000/ 28.000 (latitude/longitude) and
72.000/49.000, covering the European continent, was split into a 1,000
3 550 squares grid using the standard software settings. Cartesian
coordinates of the participating institutes were obtained from the
Getty Thesaurus of Geographic Names Online (http://www.getty.edu/
research/conducting_research/vocabularies/tgn).
Supporting Information
Figure S1. Geospatial Analyses of All Minor H Antigen Phenotype
Frequencies in the European White Populations
Red dots represent the centers from which the frequency data were
obtained. Numbers in the scaling indicate the proportion of
individuals with an immunogenic phenotype.
Found at doi:10.1371/journal.pgen.0030103.sg001 (19.6 MB AI).
Table S1. Phenotype Data of Ten Autosomally Encoded Minor H
Antigens in Six Different Ethnic Populations as Derived from the
Genotyping Frequencies
A ‘‘þ’’ indicates the immunogenic phenotype and a ‘‘ ’’ indicates the
nonimmunogenic phenotype.
Found at doi:10.1371/journal.pgen.0030103.st001 (68 KB DOC).
Table S2. Estimated Phenotype Disparity Rates Independent of the
Frequencies of the HLA restriction molecule in sib (A) and MUD (B)
transplantation settings
Disparity rates were estimated as described in the Materials and
Methods section using the genotype data results.
PLoS Genetics | www.plosgenetics.org June 2007 | Volume 3 | Issue 6 | e103 1117
Minor H Antigen Phenotype FrequenciesFound at doi:10.1371/journal.pgen.0030103.st002 (71 KB DOC).
Accession Numbers
The National Center for Biotechnology Information (NCBI) Gene
database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db¼gene) ac-
cession numbers for the minor H antigen genes used in the study are:
HMHA1 (HA-1), 23526; MYO1G (HA-2), 64005; AKAP13 (HA-3),
11214; KIAA0020 (HA-8), 9933; HMHB1 (HB-1), 57824; BCL2A1
(ACC-1 and ACC-2), 597; SP110 (SP110), 3431; CENPM (PANE1),
79019; UGT2B17 (UGT2B17), 7367.
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